CA
NZ
UK
AU
IND
US
…
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on GlucoTrack Inc (GCTK.US) is limited and the company's core business, product portfolio and financials are not readily verifiable from widely available filings. Investors evaluating the name should examine company disclosures, clinical or regulatory status and commercial traction, since long-term growth—if present—would likely depend on market demand for diabetes monitoring and adoption of any proprietary technology.
Principal investment risks include limited transparency, uncertain regulatory and clinical outcomes, weak commercial adoption, and financing and execution risk typical of small or early-stage medical-device firms.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
| Net income | -19.39M | -22.60M | -7.10M | -4.44M | -4.10M |
| Selling general administrative | 6.28M | 4.63M | 2.27M | 2.45M | 1.98M |
| Selling and marketing expenses | - | 0.39M | 0.12M | - | 0.14M |
| Gross profit | - | -0.04M | -0.01M | - | - |
| Reconciled depreciation | 0.04M | 0.04M | 0.03M | 0.02M | 0.04M |
| Ebit | -16.09M | -22.01M | -7.10M | -4.43M | -4.04M |
| Ebitda | -16.05M | -21.98M | -7.08M | -4.41M | -3.88M |
| Depreciation and amortization | 0.04M | 0.04M | 0.01M | 0.02M | 0.16M |
| Operating income | -16.09M | -14.55M | -7.10M | -4.43M | -4.04M |
| Other operating expenses | 16.09M | 14.55M | 7.10M | 4.43M | 3.98M |
| Interest expense | - | 0.63M | 0.00M | 0.00M | 4.16M |
| Interest income | - | 0.06M | 0.01M | 0.01M | 0.03M |
| Net interest income | -0.06M | -0.57M | 0.01M | 0.01M | 0.03M |
| Income tax expense | - | 22.60M | 0.85M | 0.00M | 0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 16.09M | 14.51M | 7.09M | 4.43M | 3.98M |
| Cost of revenue | - | 0.04M | 0.01M | - | - |
| Total other income expense net | -3.30M | -8.05M | 0.01M | -0.00M | -0.03M |
| Net income from continuing ops | -19.39M | -22.60M | -5.97M | -4.43M | -4.07M |
| Net income applicable to common shares | - | - | - | -4.43M | -4.07M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M |
| Other current assets | 0.28M | 0.15M | 0.38M | 0.07M | 0.04M |
| Total liab | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M |
| Total stockholder equity | 2.83M | -13.00M | 3.20M | 1.23M | 5.16M |
| Other current liab | 3.43M | 0.25M | 0.67M | 0.34M | 0.23M |
| Common stock | 0.00M | 0.00M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.00M | 0.00M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -151.84M | -132.45M | -109.85M | -101.90M | -97.47M |
| Other assets | - | - | 0.00M | 0.02M | 0.05M |
| Cash | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M |
| Total current liabilities | 4.77M | 1.27M | 1.51M | 1.01M | 0.88M |
| Net debt | -7.35M | -5.35M | -4.30M | -2.12M | -5.81M |
| Short term debt | 0.03M | 0.03M | - | - | 0.02M |
| Short long term debt | 3.18M | 0.01M | - | - | - |
| Short long term debt total | 0.03M | 0.27M | 0.20M | 0.20M | 0.25M |
| Other stockholder equity | 154.62M | 119.46M | 112.97M | 103.10M | 102.61M |
| Property plant equipment | - | - | - | 0.04M | 0.11M |
| Total current assets | 7.67M | 5.77M | 4.87M | 2.38M | 6.11M |
| Net tangible assets | - | - | - | 1.23M | 5.16M |
| Net receivables | - | - | - | - | 0.00M |
| Long term debt | 0.23M | 0.20M | 0.20M | 0.20M | 0.21M |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 1.32M | 0.99M | 0.84M | 0.67M | 0.63M |
| Accumulated other comprehensive income | 0.04M | -0.01M | 0.06M | 0.02M | -0.01M |
| Non currrent assets other | - | 0.01M | -0.00M | 0.02M | 0.05M |
| Non current assets total | 0.17M | 0.16M | 0.04M | 0.06M | 0.16M |
| Capital lease obligations | 0.03M | 0.06M | - | 0.00M | 0.04M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.10M | 0.01M | 0.00M | -0.00M |
| Change to liabilities | - | - | - | 0.07M | -0.26M |
| Total cashflows from investing activities | -0.10M | -0.10M | - | 0.00M | -0.00M |
| Net borrowings | 3.00M | 4.38M | - | - | - |
| Total cash from financing activities | 17.04M | 13.74M | 0.01M | 0.00M | 0.00M |
| Change to operating activities | - | - | - | 0.11M | -0.16M |
| Net income | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
| Change in cash | 1.76M | 1.12M | 2.18M | -3.78M | -3.77M |
| Begin period cash flow | 5.63M | 4.50M | 2.31M | 6.11M | 9.88M |
| End period cash flow | 7.38M | 5.63M | 4.49M | 2.33M | 6.11M |
| Total cash from operating activities | -15.24M | -12.49M | -6.56M | -3.73M | -3.77M |
| Issuance of capital stock | 14.21M | 9.28M | 8.73M | 0.00M | 0.00M |
| Depreciation | 0.04M | 0.04M | 0.01M | 0.02M | 0.04M |
| Change to inventory | - | - | - | 0.30M | 0.29M |
| Change to account receivables | - | - | - | 0.00M | 0.07M |
| Other cashflows from financing activities | 17.04M | 0.09M | 0.01M | 0.00M | -0.00M |
| Change to netincome | - | - | - | 0.50M | 0.31M |
| Capital expenditures | 0.10M | 0.10M | 0.00M | 0.00M | 0.01M |
| Change in working capital | 0.21M | 0.07M | 0.19M | 0.18M | -0.05M |
| Stock based compensation | 0.21M | 0.17M | 0.28M | 0.44M | 0.22M |
| Other non cash items | -15.70M | 9.83M | 0.20M | 0.06M | 0.04M |
| Free cash flow | -15.34M | -12.59M | -6.56M | -3.73M | -3.77M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GCTK GlucoTrack Inc |
-0.58 41.73% |
0.81 | - | - | 526.95 | 0.54 | 420.95 | -1.01 |
| ISRG Intuitive Surgical Inc |
-16.75 3.73% |
432.01 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
1.51 0.74% |
205.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
2.86 2.87% |
102.66 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-0.46 0.23% |
197.88 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Erez Ben-Zvi | GM & VP of Product | 1978 |
| Mr. Paul V. Goode Ph.D. | Pres & COO | 1968 |
| Ms. Jolie G. Kahn CPA, Esq. | Chief Financial Officer | 1965 |
| Mr. Avner Gal MBA, MSc.EE | Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board | 1954 |
| Mr. David Malka BA | Co-Founder | 1965 |
| Mr. James P. Thrower Ph.D. | CTO & VP of Engineering | NA |
| Mr. Paul V. Goode Ph.D. | Chief Executive Officer | 1969 |
| Mr. Mark Tapsak Ph.D. | Vice President of Technology | 1969 |
| Ms. Drinda Benjamin | Vice President of Marketing | 1976 |
| Mr. James P. Thrower Ph.D. | Vice President of Engineering | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...